Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination.
PML in a patient treated with fumaric acid.
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
LKB1/STRAD promotes axon initiation during neuronal polarization.
Multiple sclerosis: clinical presentation, diagnosis and treatment.
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Studying both sexes: a guiding principle for biomedicine.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Novantrone (mitoxantrone HCl) Injection February 2009
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Dimethyl fumarate (BG-12, Tecfidera) - NICE gives initial "no" decision
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
Antioxidant properties of the triaminopyridine, flupirtine.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Pages